On the public citation graph
EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2‐mediated MAPK pathway activation in gastric cancer cells and avatar mice
0 signed · 69 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1878-0261.12170openalex-snapshot
Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
inferredcites →https://doi.org/10.1007/s12032-014-0226-yopenalex-snapshot
Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial
inferredcites →https://doi.org/10.1016/j.cell.2010.06.011openalex-snapshot
Cell Signaling by Receptor Tyrosine Kinases
inferredcites →https://doi.org/10.1016/j.phrs.2014.06.001openalex-snapshot
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
inferredcites →https://doi.org/10.1016/s0140-6736(10)61121-xopenalex-snapshot
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)00006-6openalex-snapshot
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)00540-9openalex-snapshot
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30033-xopenalex-snapshot
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
inferredcites →https://doi.org/10.1038/bjc.2014.356openalex-snapshot
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
inferredcites →https://doi.org/10.1038/emm.2013.115openalex-snapshot
Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line
inferredcites →https://doi.org/10.1038/nature13480openalex-snapshot
Comprehensive molecular characterization of gastric adenocarcinoma
inferredcites →https://doi.org/10.1038/nrc2806openalex-snapshot
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
inferredcites →https://doi.org/10.1038/nrm1962openalex-snapshot
EGF–ERBB signalling: towards the systems level
inferredcites →https://doi.org/10.1038/srep08542openalex-snapshot
Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer
inferredcites →https://doi.org/10.1093/annonc/mdn169openalex-snapshot
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
inferredcites →https://doi.org/10.1093/annonc/mdw157openalex-snapshot
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
inferredcites →https://doi.org/10.1111/cas.13546openalex-snapshot
Antitumor activity of pan‐ HER inhibitors in HER 2‐positive gastric cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-08-3010openalex-snapshot
Eph Receptors and Ephrins in Cancer: Common Themes and Controversies
inferredcites →https://doi.org/10.1158/0008-5472.can-09-1845openalex-snapshot
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
inferredcites →https://doi.org/10.1158/0008-5472.can-15-0717openalex-snapshot
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-0701openalex-snapshot
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-3066openalex-snapshot
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2 -Amplified Gastrointestinal Carcinomas
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0754openalex-snapshot
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2 -Amplified Gastric Cancer Cells
inferredcites →https://doi.org/10.1158/1535-7163.mct-15-0737openalex-snapshot
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC
inferredcites →https://doi.org/10.1158/1541-7786.mcr-16-0482openalex-snapshot
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
inferredcites →https://doi.org/10.1158/2159-8290.cd-14-0295openalex-snapshot
EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
inferredcites →https://doi.org/10.1158/2159-8290.cd-17-1260openalex-snapshot
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma
inferredcites →https://doi.org/10.1172/jci33154openalex-snapshot
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling
inferredcites →https://doi.org/10.1186/s13045-018-0563-yopenalex-snapshot
Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
inferredcites →https://doi.org/10.1186/s13045-018-0651-zopenalex-snapshot
Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance
inferredcites →https://doi.org/10.1200/jco.2013.53.6136openalex-snapshot
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2 -Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
inferredcites →https://doi.org/10.1200/jco.2015.66.3047openalex-snapshot
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
inferredcites →https://doi.org/10.1634/theoncologist.2015-0073openalex-snapshot
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
inferredcites →https://doi.org/10.18632/oncotarget.2050openalex-snapshot
Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growthin vitroandin vivo
inferredcites →https://doi.org/10.18632/oncotarget.7746openalex-snapshot
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.5022615openalex-extracted
An Anti-Human Epha2 Monoclonal Antibody Ea2mab-7 Shows High Sensitivity for Flow Cytometry, Western Blot, and Immunohistochemical Analyses
inferred← citeshttps://doi.org/10.1002/jcp.28828openalex-snapshot
Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis
inferred← citeshttps://doi.org/10.1007/978-3-031-93894-8_8openalex-snapshot
Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy
inferred← citeshttps://doi.org/10.1007/s00109-024-02431-xopenalex-snapshot
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
inferred← citeshttps://doi.org/10.1007/s10495-024-02042-4openalex-snapshot
EFNA4-enhanced deubiquitination of SLC7A11 inhibits ferroptosis in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s13402-022-00686-5openalex-snapshot
The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma
inferred← citeshttps://doi.org/10.1016/j.abb.2021.109024openalex-snapshot
EphA2 inhibits SRA01/04 cells apoptosis by suppressing autophagy via activating PI3K/Akt/mTOR pathway
inferred← citeshttps://doi.org/10.1016/j.bbrep.2025.101998openalex-snapshot
Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applications
inferred← citeshttps://doi.org/10.1016/j.canlet.2024.217397openalex-snapshot
Polo-like kinase 4 accelerates glioma malignant progression and vasculogenic mimicry by phosphorylating EphA2
inferred← citeshttps://doi.org/10.1016/j.ctrv.2022.102418openalex-snapshot
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review
inferred← citeshttps://doi.org/10.1016/j.jbc.2026.113301openalex-snapshot
EGFR endocytosis down-regulates binding to EphA2 at the plasma membrane
inferred← citeshttps://doi.org/10.1016/j.omtn.2020.05.032openalex-snapshot
RETRACTED: Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis
inferred← citeshttps://doi.org/10.1016/j.omtn.2021.06.002openalex-snapshot
EFNA4 promotes cell proliferation and tumor metastasis in hepatocellular carcinoma through a PIK3R2/GSK3β/β-catenin positive feedback loop
inferred← citeshttps://doi.org/10.1016/j.tiv.2022.105531openalex-snapshot
Knockdown of CALM2 increases the sensitivity to afatinib in HER2-amplified gastric cancer cells by regulating the Akt/FoxO3a/Puma axis
inferred← citeshttps://doi.org/10.1038/s41419-020-02801-6openalex-snapshot
The miR-1224-5p/TNS4/EGFR axis inhibits tumour progression in oesophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1038/s41568-023-00634-xopenalex-snapshot
Eph receptors and ephrins in cancer progression
inferred← citeshttps://doi.org/10.1038/s42003-025-09213-2openalex-snapshot
Dcaf15-mediated EphA2 degradation triggers disruption of the blood-brain barrier during Streptococcus suis meningitis
inferred← citeshttps://doi.org/10.1097/cm9.0000000000003136openalex-snapshot
EGFR-mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports
inferred← citeshttps://doi.org/10.1155/2021/6670390openalex-snapshot
MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients
inferred← citeshttps://doi.org/10.1186/s12935-025-04141-xopenalex-snapshot
Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer
inferred← citeshttps://doi.org/10.1186/s13046-025-03485-6openalex-snapshot
Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer
inferred← citeshttps://doi.org/10.14740/wjon1769openalex-snapshot
The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells
inferred← citeshttps://doi.org/10.21203/rs.3.rs-796609/v1openalex-snapshot
BAP-1 Inhibits Gastric Cancer Progression via PI3K/AKT Pathway by Suppressing FOXK1 Expression
inferred← citeshttps://doi.org/10.2174/1871520620666200508090515openalex-snapshot
The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells
inferred← citeshttps://doi.org/10.3389/fbioe.2020.00389openalex-snapshot
Potential of Chitosan and Its Derivatives for Biomedical Applications in the Central Nervous System
inferred← citeshttps://doi.org/10.3389/fonc.2024.1520306openalex-snapshot
Advances and current concepts on Eph receptors and ephrins in upper digestive tract cancers
inferred← citeshttps://doi.org/10.3390/cancers13040700openalex-snapshot
EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?
inferred← citeshttps://doi.org/10.3390/cancers13051010openalex-snapshot
EPHA2 Interacts with DNA-PKcs in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells
inferred← citeshttps://doi.org/10.3390/pharmaceutics14091759openalex-snapshot
Two-in-One Nanoparticle Formulation to Deliver a Tyrosine Kinase Inhibitor and microRNA for Targeting Metabolic Reprogramming and Mitochondrial Dysfunction in Gastric Cancer
inferred← citeshttps://doi.org/10.37748/2686-9039-2021-2-4-4openalex-snapshot
Methods for modeling tumor growth in mice in experimental studies of human gastric cancer
inferred← citeshttps://doi.org/10.3892/ijo.2024.5629openalex-snapshot
Xenograft and organoid models in developing precision medicine for gastric cancer (Review)
inferred← citeshttps://doi.org/10.4251/wjgo.v15.i10.1739openalex-snapshot
Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatin via inhibiting PI3K/AKT/mTOR and MAPK signaling
inferred← citeshttps://doi.org/10.5808/gi.22069openalex-snapshot
In-silico and structure-based assessment to evaluate pathogenicity of missense mutations associated with non-small cell lung cancer identified in the Eph-ephrin class of proteins
inferred← citeshttps://doi.org/10.7717/peerj.16951openalex-snapshot
Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.